Suggestions from relevant parties to disseminate results to trial participants and patient groups (n=1818)
| Suggested dissemination | N (%) of trials | ||
| Yes | No | Don’t know | |
| To trial participants | |||
| Principal investigator | 907 (50) | 488 (27) | 184 (10) |
| Other members of the research team | 708 (39) | 598 (33) | 217 (12) |
| Patient and public involvement representative(s) involved with the trial | 260 (14) | 901 (50) | 287 (16) |
| Research funder(s) | 314 (17) | 882 (49) | 251 (14) |
| Ethical or institutional review board | 333 (18) | 872 (48) | 258 (14) |
| Academic institution | 302 (17) | 880 (48) | 259 (14) |
| Regulatory bodies | 144 (8) | 931 (51) | 320 (18) |
| To patient groups | |||
| Principal investigator | 706 (39) | 626 (34) | 210 (12) |
| Other members of the research team | 579 (32) | 683 (38) | 240 (13) |
| Patient and public involvement representative(s) involved with the trial | 212 (12) | 922 (51) | 300 (17) |
| Research funder(s) | 252 (14) | 903 (50) | 281 (16) |
| Ethical or institutional review board | 148 (8) | 979 (54) | 296 (16) |
| Academic institution | 238 (13) | 917 (50) | 284 (16) |
| Regulatory bodies | 83 (5) | 971 (53) | 339 (19) |
Percentages do not sum to 100% due to missing data.